Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up
Por:
Rodríguez Almaraz E, Sáez-Comet L, Casellas M, Delgado P, Ugarte A, Vela C, Martínez Sánchez N, Galindo-Izquierdo M, Espinosa G, Marco B, Martínez López JA, Robles A, Martínez-Taboada V, Bartha JL and Ruiz-Irastorza G
Publicada:
1 mar 2019
Ahead of Print:
25 nov 2019
Categoría:
Rheumatology
Resumen:
Objective: In order to agree on the fundamental aspects related to the management of pregnancy in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), the Spanish Societies of Gynaecology and Obstetrics, Internal Medicine and Rheumatology set up a working group for the preparation of three consensus documents.
Methods: Each of the Scientific Societies involved proposed five representatives based on their experience in the field of pregnancy control in patients with autoimmune diseases. The recommendations were developed following the Delphi methodology.
Results: This second document contains the recommendations regarding the management of pregnancy in women with SLE and APS, including complications such as lupus activity, congenital heart block, thrombotic and obstetric manifestations of APS and placental vascular disease.
Conclusions: These multidisciplinary recommendations are considered decision-making tools for clinicians involved in the care of patients with SLE/APS during pregnancy. (C) 2019 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.
Filiaciones:
Rodríguez Almaraz E:
Servicio de Reumatología, Hospital 12 de Octubre, Madrid, España
Sáez-Comet L:
Unidad de Enfermedades Autoinmunes Sistémicas (UEAS), Servicio de Medicina Interna, Hospital Universitario Miguel Servet, Zaragoza, España
Casellas M:
Unitat Alt Risc Obstetric, Vall d' Hebron Hospital Campus, Barcelona, España
Delgado P:
Servicio de Obstetricia y Ginecología, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Barakaldo, Bizkaia, España
Ugarte A:
Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, BioCruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Bizkaia, España
Vela C:
Sección de Reumatología, Hospital General Universitario Alicante, Instituto de Investigación Sanitaria y Biomédica ISABIAL - FISABIO, Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, España
Martínez Sánchez N:
Servicio de Ginecología y Obstetricia, Hospital Universitario La Paz, Madrid, España
Galindo-Izquierdo M:
Servicio de Reumatología, Hospital 12 de Octubre, Madrid, España
Espinosa G:
Servicio de Enfermedades Autoinmune, Hospital Clinic, Agresión biológica y mecanismos de respuesta, IDIBAPS, Barcelona, Universitat de Barcelona, Barcelona, España
Marco B:
Servicio de Ginecología y Obstetricia, HUP La Fe, Valencia, España
Martínez López JA:
Servicio de Reumatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, España
Robles A:
Servicio de Medicina Interna, Hospital Universitario La Paz, Madrid, España
Martínez-Taboada V:
Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, IDIVAL, Facultad de Medicina, Universidad de Cantabria, Santander, Cantabria, España
Bartha JL:
Servicio de Ginecología y Obstetricia, Hospital Universitario La Paz, Madrid, España
Ruiz-Irastorza G:
Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, BioCruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Bizkaia, España
Green Accepted
FULL TEXT
 |
Published Version |
This policy does not allow for Open Access for this version. |
| No Accesible |
|